Scott S. Tykodi

Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa

Also affiliated with University of Washington, University of Washington Medical Center, Fred Hutch Cancer Center

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 5%percentile

0.470Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Single cell atlas of kidney cancer endothelial cells reveals distinct expression profiles and phenotypes

BJC Reports(2024)10.1038/s44276-024-00047-9

Top 40%

0.470DataRank

Top 40%10 citations

Chris P. Miller, Jun Xue, Ying Zheng, Edus H. Warren, Scott S. Tykodi +2 more

Papers

Driven by 17 papers — median percentile 30. Top paper: “Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial”.

Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2020-000891

N/A

5.8DataRank · unranked

225 citations

Bernard Escudier, David F. McDermott, Osvaldo Arén Frontera, Bohuslav Melichar, Thomas Powles +24 more

Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma

Journal for ImmunoTherapy of Cancer(2022)10.1136/jitc-2022-005445

N/A

2.7DataRank · unranked

69 citations

Sabina Signoretti, Toni K. Choueiri, David F. McDermott, Robert J. Motzer, Saby George +9 more

Mobilization of pre-existing polyclonal T cells specific to neoantigens but not self-antigens during treatment of a patient with melanoma with bempegaldesleukin and nivolumab

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2020-001591

N/A

0.547DataRank · unranked

9 citations

Naina Singhi, Brenda L. Jesernig, Kelly G. Paulson, Jonathan Zalevsky, Ernesto Iacucci +3 more

Single cell atlas of kidney cancer endothelial cells reveals distinct expression profiles and phenotypes

BJC Reports(2024)10.1038/s44276-024-00047-9

Top 40%

0.470DataRank

Top 40%10 citations

Chris P. Miller, Jun Xue, Ying Zheng, Edus H. Warren, Scott S. Tykodi +2 more

First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-4256

N/A

0DataRank · unranked

98 citations

Justin F. Gainor, Margaret K. Callahan, Gerald S. Falchook, Russell K. Pachynski, Patricia LoRusso +29 more

Associating sleep problems with advanced cancer diagnosis, and immune checkpoint treatment outcomes: a pilot study

Supportive Care in Cancer(2022)10.1007/s00520-022-06825-w

N/A

0DataRank · unranked

8 citations

Ulrike Peters, Nathaniel F. Watson, Scott S. Tykodi, Evan Hall, Allison Silverman +9 more

Integrated TCR repertoire analysis and single-cell transcriptomic profiling of tumor-infiltrating T cells in renal cell carcinoma identifies shared and tumor-restricted expanded clones with unique phenotypes

Frontiers in Oncology(2022)10.3389/fonc.2022.952252

N/A

0DataRank · unranked

6 citations

Alicia J. Morales, Andrea Towlerton, Shreeram Akilesh, Chris P. Miller, Scott S. Tykodi +2 more

Therapeutic targeting of tumor spheroids in a 3D microphysiological renal cell carcinoma-on-a-chip system

Neoplasia(2023)10.1016/j.neo.2023.100948

N/A

0DataRank · unranked

17 citations

Megan K. Fung, Carla A. Jaeger-Ruckstuhl, Yuexin Xu, Edus H. Warren, Shreeram Akilesh +2 more

Supplementary Data from First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

Figshare(2023)10.1158/1078-0432.22487576.v1

Top 100%

0DataRank

Top 100%0 citations

Justin F. Gainor, Margaret K. Callahan, Gerald S. Falchook, Russell K. Pachynski, Patricia LoRusso +29 more

Data from C19orf48 Encodes a Minor Histocompatibility Antigen Recognized by CD8+ Cytotoxic T Cells from Renal Cell Carcinoma Patients

(2023)10.1158/1078-0432.c.6516948

N/A

0DataRank · unranked

0 citations

Nobuharu Fujii, Nathalie Vigneron, Sharon Lu, Jeffrey K. Mito, Maureen X. Miranda +9 more

Data from Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma

(2023)10.1158/1078-0432.c.6529871

N/A

0DataRank · unranked

0 citations

Sabina Signoretti, Toni K. Choueiri, David F. McDermott, Robert J. Motzer, Abdallah Flaifel +19 more

Data from C19orf48 Encodes a Minor Histocompatibility Antigen Recognized by CD8+ Cytotoxic T Cells from Renal Cell Carcinoma Patients

(2023)10.1158/1078-0432.c.6516948.v1

N/A

0DataRank · unranked

0 citations

Nobuharu Fujii, Nathalie Vigneron, Sharon Lu, Jeffrey K. Mito, Maureen X. Miranda +9 more

Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial

Cancer(2020)10.1002/cncr.33033

N/A

0DataRank · unranked

340 citations

Bernard Escudier, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi +26 more

A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer

ESMO Open(2025)10.1016/j.esmoop.2025.104536

N/A

0DataRank · unranked

60 citations

Martin H. Voss, Hussein A. Tawbi, Michael S. Gordon, Scott S. Tykodi, Elaine T. Lam +13 more

Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-2063

N/A

0DataRank · unranked

243 citations

Sabina Signoretti, Toni K. Choueiri, David F. McDermott, Robert J. Motzer, Abdallah Flaifel +19 more

Predictive Lifestyle Markers for Efficacy of Cancer Immune Checkpoint Inhibitors: A Commentary

Future Oncology(2021)10.2217/fon-2020-0730

N/A

0DataRank · unranked

1 citations

Scott S. Tykodi, Evan Hall, John A. Thompson, Nathaniel F. Watson, Sylvia M. Lee +8 more

Neoantigen-specific CD4+ T cells in human melanoma have diverse differentiation states and correlate with CD8+ T cell, macrophage, and B cell function

Cancer Cell(2022)10.1016/j.ccell.2022.03.006

N/A

0DataRank · unranked

146 citations

Sylvia M. Lee, Carolyn Shasha, Naina Singhi, Julia Szeto, Ata S. Moshiri +17 more

Scott S. Tykodi

Indexed papers

Top data-sharing exemplar

Papers